As of 2025-07-03, the EV/EBITDA ratio of Arcus Biosciences Inc (RCUS) is 30.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Arcus's latest enterprise value is 957.60 mil USD. Arcus's TTM EBITDA according to its financial statements is 31.00 mil USD. Dividing these 2 quantities gives us the above Arcus EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 13.7x | 13.2x |
| Forward P/E multiples | 20.6x - 30.9x | 25.8x |
| Fair Price | 3.29 - 8.59 | 5.26 |
| Upside | -61.7% - 0.0% | -38.8% |
| Date | EV/EBITDA |
| 2025-07-02 | 31.03 |
| 2025-07-01 | 30.10 |
| 2025-06-30 | 29.35 |
| 2025-06-27 | 28.70 |
| 2025-06-26 | 30.58 |
| 2025-06-25 | 30.99 |
| 2025-06-24 | 31.44 |
| 2025-06-23 | 31.03 |
| 2025-06-20 | 30.99 |
| 2025-06-18 | 30.62 |
| 2025-06-17 | 31.27 |
| 2025-06-16 | 32.60 |
| 2025-06-13 | 33.11 |
| 2025-06-12 | 33.49 |
| 2025-06-11 | 32.56 |
| 2025-06-10 | 35.77 |
| 2025-06-09 | 35.19 |
| 2025-06-06 | 35.60 |
| 2025-06-05 | 34.44 |
| 2025-06-04 | 34.34 |
| 2025-06-03 | 35.81 |
| 2025-06-02 | 33.04 |
| 2025-05-30 | 32.05 |
| 2025-05-29 | 34.03 |
| 2025-05-28 | 32.73 |
| 2025-05-27 | 32.39 |
| 2025-05-23 | 32.36 |
| 2025-05-22 | 31.54 |
| 2025-05-21 | 30.96 |
| 2025-05-20 | 31.85 |
| 2025-05-19 | 31.30 |
| 2025-05-16 | 30.79 |
| 2025-05-15 | 30.82 |
| 2025-05-14 | 30.72 |
| 2025-05-13 | 31.16 |
| 2025-05-12 | 31.61 |
| 2025-05-09 | 29.83 |
| 2025-05-08 | 30.69 |
| 2025-05-07 | 28.91 |
| 2025-05-06 | 29.28 |
| 2025-05-05 | 32.09 |
| 2025-05-02 | 32.70 |
| 2025-05-01 | 30.99 |
| 2025-04-30 | 31.44 |
| 2025-04-29 | 29.32 |
| 2025-04-28 | 29.73 |
| 2025-04-25 | 29.90 |
| 2025-04-24 | 30.28 |
| 2025-04-23 | 29.25 |
| 2025-04-22 | 29.18 |